March 9, 2022 12:57 PM ESTUpdated 01:53 PM
R&D
Pharma

A trio of amy­loid-tar­get­ed Alzheimer's drugs will soon see key re­sults, but an an­a­lyst pre­dicts on­ly 50-50 odds for one

Zachary Brennan

Senior Editor

Pig­gy­back­ing off of Bio­gen’s con­tro­ver­sial ac­cel­er­at­ed ap­proval for Aduhelm, new piv­otal da­ta are com­ing soon from three oth­er amy­loid-tar­get­ed Alzheimer’s drugs from Roche, Eli Lil­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis claims best earn­ings in years, val­i­dat­ing shift to pure-play strat­e­gy

Roche sep­a­rates CFO, in­for­mat­ics posts; Lil­ly ex­ecs land at Kail­era, Neu­ro­crine

Ver­tex's non-opi­oid pain drug is ap­proved by FDA, bring­ing first of new class to mar­ket

Fri­day IPO dou­ble­head­er from Maze and Met­sera brings life to biotech de­buts

Ab­b­Vie rais­es Skyrizi and Rin­voq es­ti­mates, pre­dicts $31B in 2027 sales

sponsored

Why the pre­mier re­cruit­ment agency in the world is giv­ing up re­cruit­ing, and spon­sors should, too

A service from the Financial Times